USANA Health Sciences Reports Q4 Net Loss, 74% FY25 EPS Decline Amid Impairment & Restructuring Charges

summarizeSummary

USANA Health Sciences reported a Q4 2025 net loss and a 74% decline in FY 2025 diluted EPS, primarily due to $13.5 million in impairment and cost realignment charges. The company's core nutritional business continues to decline, while acquired omnichannel brands, Hiya and Rise Wellness, are driving overall sales growth and are central to the mixed FY 2026 outlook.

check_boxKey Events

• Q4 2025 Net Loss and EPS Decline

  The company reported a net loss of $1.8 million for Q4 2025, translating to a diluted EPS of -$0.10, a significant drop from net earnings of $4.5 million and $0.23 diluted EPS in Q4 2024.

• FY 2025 Earnings Plummet 74%

  For the full fiscal year 2025, net earnings attributable to USANA decreased 74% to $10.8 million, with diluted EPS falling to $0.58 from $2.19 in fiscal year 2024.

• Significant One-Time Charges Impact Results

  Q4 2025 results were negatively impacted by a $7.0 million non-cash impairment charge on goodwill and intangibles and a $6.5 million charge for cost realignment initiatives, partially offset by a $3.2 million gain on asset disposal.

• Core Nutritional Business Continues to Decline

  USANA Active Customers decreased from 454,000 to 387,000 year-over-year. The core nutritional business is projected to decline 0-5% in fiscal year 2026, despite sequential stabilization signs in Q4 2025.

auto_awesomeAnalysis

USANA Health Sciences reported a net loss of $1.8 million for Q4 2025, resulting in a diluted EPS of -$0.10, a significant decline from $0.23 in Q4 2024. For the full fiscal year 2025, net earnings plummeted 74% to $10.8 million, with diluted EPS falling to $0.58 from $2.19 in the prior year. These results were heavily impacted by a $7.0 million non-cash impairment charge and a $6.5 million cost realignment charge, partially offset by a $3.2 million gain on asset disposal. The core nutritional business continues to face challenges, with active customer counts declining and an anticipated 0-5% sales decline in fiscal year 2026. While the company's omnichannel strategy, driven by Hiya and Rise Wellness acquisitions, shows strong growth and is expected to contribute significantly to future sales, it has not yet offset the core business's struggles or the impact of one-time charges on profitability. The fiscal year 2026 outlook projects a recovery in net earnings and EPS, but still below fiscal year 2024 levels, indicating ongoing operational adjustments.